The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 Cancer Biology Research) to the University of Pittsburgh totaling $585,931.00 to develop a comprehensive framework for evaluating the molecular congruence and representative fidelity of cancer models, such as cell lines, patient-derived xenografts (PDX), and patient-derived organoids (PDO), compared to human tumors. Specifically, the project aims to: (1) identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer; (2) perform subclone-based congruence assessment and selection of cancer models; and (3) decipher temporal changes in the congruence of patient-derived cancer models. The goal is to guide the selection of the most representative cancer models for translational and preclinical research towards precision medicine. The award period runs from February 2025 through January 2030.
Generated 3/4/25, 8:04 AM